Skip to main
ETON
ETON logo

ETON Stock Forecast & Price Target

ETON Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eton Pharmaceuticals, Inc. is projected to see significant revenue growth associated with its product Khindivi, which is expected to peak at $28 million by 2030, up from $3 million in 2025. The company's probability of launching Khindivi has been raised to 100%, with expectations that its launch will occur in June rather than the previously anticipated second quarter of 2025, reflecting an increased confidence in its market penetration potential. Additionally, Eton's strong track record in commercial execution suggests that 2025 could be a pivotal year for revenue growth, bolstering a positive outlook for the company's financial performance.

Bears say

Eton Pharmaceuticals faces a challenging outlook due to the assumptions of an 11% discount rate and a low terminal growth rate of 2%, which may limit future profitability and growth potential. Despite a modest increase in the projected price target from $33 to $35 per diluted share, the financial projections indicate that the growth metrics remain subdued. This combination of high discounting and low growth expectations raises concerns about the sustainability of Eton Pharmaceuticals's financial performance in the competitive specialty pharmaceutical market.

ETON has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eton Pharmaceuticals Inc (ETON) Forecast

Analysts have given ETON a Strong Buy based on their latest research and market trends.

According to 3 analysts, ETON has a Strong Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eton Pharmaceuticals Inc (ETON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.